Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991 Aug;18(2):240-8.
doi: 10.1016/s0272-6386(12)80885-7.

Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL)

Affiliations

Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL)

G Banfi et al. Am J Kidney Dis. 1991 Aug.

Abstract

The frequency of renal vascular lesions (RVL) and their relevance in the progression of renal damage were evaluated by the Pathology Group of the "Gruppo Italiano per lo Studio della Nefrite Lupica" (GISNEL). Of 285 patients with lupus nephritis collected from 20 nephrology centers in Italy and classified according to World Health Organization (WHO) criteria, 79 cases (27.7%) with RVL were identified and classified as follows: (1) lupus vasculopathy (n = 27); (2) hemolytic-uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP) malignant hypertension-like lesions (n = 24); (3) vasculitis (n = 8); (4) arterio-arteriosclerosis (n = 20). At the time of renal biopsy, patients with RVL had mean serum creatinine levels significantly higher than patients without RVL (201.8 +/- 195.9 mumol/L [2.2 +/- 2.2 mg/dL] v 108.1 +/- 108.0 mumol/L [1.2 +/- 1.2 mg/dL]; P less than 0.01). Hypertension was more frequent in patients with RVL than in those without (68.4% v 30.5%; P less than 0.01). The probability of kidney survival assessed according to the Kaplan-Meier method at 5 and 10 years was, respectively, 74.3% +/- 5.9% and 58.0% +/- 8.9% in patients with RVL, compared with 89.6% +/- 2.7% and 85.9% +/- 3.7% in patients without RVL. However, the two groups did not differ significantly as regards overall survival, the probability of survival at 5 and 10 years being 86.5% +/- 4.5% and 78.8% +/- 6.6% in patients with RVL and 92.2% +/- 2.2% and 83.3% +/- 4.4% in patients without RVL.(ABSTRACT TRUNCATED AT 250 WORDS)

PubMed Disclaimer

Similar articles

Cited by

  • Lupus Vasculitis: An Overview.
    Leone P, Prete M, Malerba E, Bray A, Susca N, Ingravallo G, Racanelli V. Leone P, et al. Biomedicines. 2021 Nov 5;9(11):1626. doi: 10.3390/biomedicines9111626. Biomedicines. 2021. PMID: 34829857 Free PMC article. Review.
  • Ten tips in lupus nephritis management.
    Teoh STY, Yap DYH, Chan TM. Teoh STY, et al. Clin Kidney J. 2024 Nov 22;18(1):sfae376. doi: 10.1093/ckj/sfae376. eCollection 2025 Jan. Clin Kidney J. 2024. PMID: 39872638 Free PMC article. Review.
  • The Revisited Classification of GN in SLE at 10 Years: Time to Re-Evaluate Histopathologic Lesions.
    Wilhelmus S, Alpers CE, Cook HT, Ferrario F, Fogo AB, Haas M, Joh K, Noël LH, Seshan SV, Bruijn JA, Bajema IM. Wilhelmus S, et al. J Am Soc Nephrol. 2015 Dec;26(12):2938-46. doi: 10.1681/ASN.2015040384. Epub 2015 Jul 7. J Am Soc Nephrol. 2015. PMID: 26152271 Free PMC article. Review.
  • A case of lupus vasculopathy presenting favorable renal outcome.
    Ishizaki Y, Aizawa A, Ochiai S, Minakawa A, Miyauchi S, Umekita K, Sato Y, Ogawa Y, Kushida Y, Okayama A, Uesugi N, Fujimoto S. Ishizaki Y, et al. CEN Case Rep. 2020 Feb;9(1):74-80. doi: 10.1007/s13730-019-00431-2. Epub 2019 Dec 20. CEN Case Rep. 2020. PMID: 31863345 Free PMC article.
  • II Brazilian Society of Rheumatology consensus for lupus nephritis diagnosis and treatment.
    Reis-Neto ETD, Seguro LPC, Sato EI, Borba EF, Klumb EM, Costallat LTL, Medeiros MMDC, Bonfá E, Araújo NC, Appenzeller S, Montandon ACOES, Yuki EFN, Teixeira RCA, Telles RW, Egypto DCSD, Ribeiro FM, Gasparin AA, Junior ASA, Neiva CLS, Calderaro DC, Monticielo OA. Reis-Neto ETD, et al. Adv Rheumatol. 2024 Jun 18;64(1):48. doi: 10.1186/s42358-024-00386-8. Adv Rheumatol. 2024. PMID: 38890752

LinkOut - more resources